title: Imatinib-induced hand-foot syndrome in a patient with metastatic gastrointestinal stromal tumor.
authors.forename: Maxime
authors.initials: M
authors.lastname: Battistella
authors.forename: Guillemette
authors.initials: G
authors.lastname: Frémont
authors.forename: Marie-Dominique
authors.initials: MD
authors.lastname: Vignon-Pennamen
authors.forename: Jean-Marc
authors.initials: JM
authors.lastname: Gornet
authors.forename: Louis
authors.initials: L
authors.lastname: Dubertret
authors.forename: Manuelle
authors.initials: M
authors.lastname: Viguier
mesh_terms: D001549:Benzamides; D001707:Biopsy, Needle; D003875:Drug Eruptions / Q000209:etiology; D004890:Erythema / Q000139:chemically induced*; D005500:Follow-Up Studies; D005533:Foot Dermatoses / Q000139:chemically induced* / Q000473:pathology; D046152:Gastrointestinal Stromal Tumors / Q000188:drug therapy* / Q000473:pathology; D006229:Hand Dermatoses / Q000139:chemically induced* / Q000473:pathology; D006801:Humans; D000068877:Imatinib Mesylate; D007150:Immunohistochemistry; D008113:Liver Neoplasms / Q000556:secondary; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D010879:Piperazines / Q000009:adverse effects* / Q000627:therapeutic use; D047428:Protein Kinase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D011706:Pyloric Antrum; D011743:Pyrimidines / Q000009:adverse effects* / Q000627:therapeutic use; D018570:Risk Assessment; D013274:Stomach Neoplasms / Q000556:secondary; D013577:Syndrome
chemical_list: D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D000068877:Imatinib Mesylate